Back to Search
Start Over
From single drug targets to synergistic network pharmacology in ischemic stroke.
- Source :
-
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2019 Apr 02; Vol. 116 (14), pp. 7129-7136. Date of Electronic Publication: 2019 Mar 20. - Publication Year :
- 2019
-
Abstract
- Drug discovery faces an efficacy crisis to which ineffective mainly single-target and symptom-based rather than mechanistic approaches have contributed. We here explore a mechanism-based disease definition for network pharmacology. Beginning with a primary causal target, we extend this to a second using guilt-by-association analysis. We then validate our prediction and explore synergy using both cellular in vitro and mouse in vivo models. As a disease model we chose ischemic stroke, one of the highest unmet medical need indications in medicine, and reactive oxygen species forming NADPH oxidase type 4 ( Nox4 ) as a primary causal therapeutic target. For network analysis, we use classical protein-protein interactions but also metabolite-dependent interactions. Based on this protein-metabolite network, we conduct a gene ontology-based semantic similarity ranking to find suitable synergistic cotargets for network pharmacology. We identify the nitric oxide synthase ( Nos1 to 3 ) gene family as the closest target to Nox4 Indeed, when combining a NOS and a NOX inhibitor at subthreshold concentrations, we observe pharmacological synergy as evidenced by reduced cell death, reduced infarct size, stabilized blood-brain barrier, reduced reoxygenation-induced leakage, and preserved neuromotor function, all in a supraadditive manner. Thus, protein-metabolite network analysis, for example guilt by association, can predict and pair synergistic mechanistic disease targets for systems medicine-driven network pharmacology. Such approaches may in the future reduce the risk of failure in single-target and symptom-based drug discovery and therapy.<br />Competing Interests: Conflict of interest statement: H.H.H.W.S. is a cofounder of a biotech company, Vasopharm, engaged in the development of small-molecule NOS inhibitors, currently in stage III clinical development. However, H.H.H.W.S. has no operative role in the company and holds less than 1% of shares.<br /> (Copyright © 2019 the Author(s). Published by PNAS.)
- Subjects :
- Animals
Blood-Brain Barrier metabolism
Brain Ischemia prevention & control
Cell Death drug effects
Disease Models, Animal
Drug Combinations
Drug Synergism
Female
Male
Mice
NADPH Oxidase 4 drug effects
NG-Nitroarginine Methyl Ester pharmacology
Nitric Oxide Synthase drug effects
Nitric Oxide Synthase genetics
Nitric Oxide Synthase Type I genetics
Nitric Oxide Synthase Type I metabolism
Nitric Oxide Synthase Type II genetics
Nitric Oxide Synthase Type II metabolism
Nitric Oxide Synthase Type III genetics
Nitric Oxide Synthase Type III metabolism
Pyrazoles pharmacology
Pyridones pharmacology
Reactive Oxygen Species metabolism
Stroke prevention & control
Brain Ischemia drug therapy
Brain Ischemia metabolism
Drug Discovery
NADPH Oxidase 4 metabolism
Nitric Oxide Synthase metabolism
Stroke drug therapy
Stroke metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1091-6490
- Volume :
- 116
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- Proceedings of the National Academy of Sciences of the United States of America
- Publication Type :
- Academic Journal
- Accession number :
- 30894481
- Full Text :
- https://doi.org/10.1073/pnas.1820799116